elotuzumab
Sign in to saveAlso known as Empliciti
Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetam
Research
480 papersvia PubMed
Wikidata facts
- Subclass of
- monoclonal antibody
- Has use
- medication
Show 1 more fact
- subject has role
- monoclonal antibody
Sources (3)
via Wikidata · CC0
~6 min read
Encyclopedic overview
11 sectionsContents
- Medical use
- Multiple myeloma
- Dosage and administration
- In combination with lenalidomide and dexamethasone
- In combination with pomalidomide and dexamethasone
- Adverse effects
- Mechanism of action
- Clinical trials
- Eloquent 2 trial
- Eloquent 3 trial
- References
Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie.
Common side effects of elotuzumab with lenalidomide and dexamethasone includes fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, and pneumonia. The most common side effects of elotuzumab with pomalidomide and dexamethasone includes constipation and hyperglycemia. There is no available information for the use of elotuzumab in pregnant women.
Excerpted from Wikipedia’s “elotuzumab” article, available under the CC BY-SA 4.0 licence.